DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

The Next Evolution of MRI and Robotics

Volunteers Needed!

FOR A RESEARCH STUDY ON OFFICE-BASED MRI
*You will be compensated for taking part in this study ($50/MRI for a total of $100)..
neuro42, a Bay Area medical device company, is conducting a research study to do MR scans of the head using their portable MR scanner. They are comparing MR scans on their system to a conventional MR scanner. 

They are recruiting subjects who have had a brain condition, injury, pathology and/or disease that can be seen on an MRI scan, including but not limited to:: 

•. Stroke
• Traumatic brain injury
• Hydrocephalus
• Brain tumor or cyst
• Brain hemorrhage
• Epilepsy

*This research study will not involve treatment of any medical condition.
YOU ARE ELIGIBLE IF YOU CAN ANSWER YES TO ALL OF THE FOLLOWING:
Are you in the San Francisco Bay area or the *Seattle area?
Are you able to undergo an MRI scan?
Are you 18 years of age or older?
Are you willing to have a 1-2 hour, in-person MRI at the neuro42 office in San Francisco?
Are you willing to have a 1-2 hour, in-person MRI at the UCSF Mission Bay Campus?
*If you reside in the Seattle area, neuro42 will cover the cost of 1 round-trip airline ticket to San Francisco along with a one night hotel stay in addition to the compensated MRI's at $50/each for a total of $100.
neuro42 video place holder:
If you are interested in participating in this study, or if you have questions, please complete the initial inquiry form by clicking on the button below.
YES! I WOULD LIKE TO PARTICIPATE.

Conceived at neuro42. Designed for You.

Portable, easy-to-use MRI, artificial intelligence and robotics platform for screening, diagnosis 
and live image guided interventions.

Requires minimal setup blending seamlessly into the procedural workflow, enriching the patient 
and physician experience.

About neuro42
neuro42, Inc. is a medtech Company advancing futuristic technologies for screening, diagnosis, and targeted treatment of neurological conditions. The Company is developing and commercializing a portable MRI, robotic and AI platform, backed by over 30 patents, for point-of-care imaging and interventions under live image guidance. neuro42 is founded by a team of serial entrepreneurs and innovators with a mission to improve lives through its patient-centric solutions.

Fusing MRI, AI and Robotics

Our product suite unifies an ecosystem of patented technologies to enable efficient diagnosis and targeted treatment of neurological conditions.

Intraoperative robotic guidance under live imaging, powered by intelligent procedural planning and predictive analysis, is the future we envision.
Witness the Future of Imaging
MRI flexibility and portability now has meaning!

The neuro42 concierge MRI at your local clinic, urgent care or retail location is imminent.

Surgeons Love the neuro42 Platform...

"Every comprehensive stroke center will want to have the neuro42 MRI. The low field mobile MRI would be beneficial in confirming my tumor resections and stereotactic interventions like biopsies, lasers and DBS."
Amrith Jamoona, MD 
Neurosurgeon at Sutter Medical Center, CA
"neuro42's live MRI will change the paradigm of intraoperative image guidance in surgical cases such as shunts, biopsies and laser therapy. The possibility to account for brain shift during a tumor resection is a compelling argument for its future adoption."
Abhay Sanan, MD 
Neurosurgeon at Center for Neurosciences, AZ

"The portability of neuro42 MRI can be of great value for precise and rapid evaluation of intraoperative resection of any brain lesion. It can allow timely radiological evaluation for patients in critical care unit deemed to be too unstable to be transported to the conventional MRI suite."
Marco Marsella, MD 
Neurosurgeon at Banner Health, AZ

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram